Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β₃-adrenoceptor agonist for treatment of overactive bladder.

Eltink C, Lee J, Schaddelee M, Zhang W, Kerbusch V, Meijer J, van Marle S, Grunenberg N, Kowalski D, Drogendijk T, Moy S, Iitsuka H, van Gelderen M, Matsushima H, Sawamoto T.

Int J Clin Pharmacol Ther. 2012 Nov;50(11):838-50. doi: 10.5414/CP201782.

PMID:
22943933
3.

Mirabegron: β3-adrenergic receptor agonist for the treatment of overactive bladder.

Bridgeman MB, Friia NJ, Taft C, Shah M.

Ann Pharmacother. 2013 Jul-Aug;47(7-8):1029-38. doi: 10.1345/aph.1S054. Epub 2013 Jun 11. Review.

PMID:
23757386
4.

The pharmacokinetic evaluation of mirabegron as an overactive bladder therapy option.

Kashyap M, Tyagi P.

Expert Opin Drug Metab Toxicol. 2013 May;9(5):617-27. doi: 10.1517/17425255.2013.786700. Epub 2013 Apr 4. Review.

PMID:
23550899
5.

Mirabegron: a safety review.

Tyagi P, Tyagi V, Chancellor M.

Expert Opin Drug Saf. 2011 Mar;10(2):287-94. doi: 10.1517/14740338.2011.542146. Epub 2010 Dec 9. Review.

PMID:
21142693
6.

Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a β₃-adrenoceptor agonist (Mirabegron) for overactive bladder (OAB).

Rossanese M, Novara G, Challacombe B, Iannetti A, Dasgupta P, Ficarra V.

BJU Int. 2015 Jan;115(1):32-40. doi: 10.1111/bju.12730. Epub 2014 Jul 27. Review.

7.

What do we know and not know about mirabegron, a novel β3 agonist, in the treatment of overactive bladder?

Caremel R, Loutochin O, Corcos J.

Int Urogynecol J. 2014 Feb;25(2):165-70. doi: 10.1007/s00192-013-2161-4. Epub 2013 Aug 7. Review.

PMID:
23922008
8.

Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence.

Sacco E, Bientinesi R, Tienforti D, Racioppi M, Gulino G, D'Agostino D, Vittori M, Bassi P.

Expert Opin Drug Discov. 2014 Apr;9(4):433-48. doi: 10.1517/17460441.2014.892923. Epub 2014 Feb 22. Review.

PMID:
24559030
9.

Mirabegron in the treatment of overactive bladder.

Leone Roberti Maggiore U, Cardozo L, Ferrero S, Sileo F, Cola A, Del Deo F, Torella M, Colacurci N, Candiani M, Salvatore S.

Expert Opin Pharmacother. 2014 Apr;15(6):873-87. doi: 10.1517/14656566.2014.898752. Review. Erratum in: Expert Opin Pharmacother. 2014 May;15(7):1059. Del Deo, Fabio [added].

PMID:
24646053
10.

Selective β₃-adrenoceptor agonists for the treatment of overactive bladder.

Andersson KE, Martin N, Nitti V.

J Urol. 2013 Oct;190(4):1173-80. doi: 10.1016/j.juro.2013.02.104. Epub 2013 Feb 28. Review.

PMID:
23458471
11.

Use of mirabegron in treating overactive bladder.

Bhide AA, Digesu GA, Fernando R, Khullar V.

Int Urogynecol J. 2012 Oct;23(10):1345-8. Epub 2012 Mar 13. Review.

PMID:
22411211
12.

Mirabegron for overactive bladder: a novel, first-in-class β3-agonist therapy.

Imran M, Najmi AK, Tabrez S.

Urol J. 2013 Sep 26;10(3):935-40. Review.

13.

Cardiovascular Safety of β3-adrenoceptor Agonists for the Treatment of Patients with Overactive Bladder Syndrome.

Rosa GM, Ferrero S, Nitti VW, Wagg A, Saleem T, Chapple CR.

Eur Urol. 2016 Feb;69(2):311-23. doi: 10.1016/j.eururo.2015.09.007. Epub 2015 Sep 28. Review.

14.

β3-receptor agonists for overactive bladder--new frontier or more of the same?

Andersson KE.

Curr Urol Rep. 2013 Oct;14(5):435-41. doi: 10.1007/s11934-013-0335-8. Review.

PMID:
23677692
15.

Safety and tolerability of β3-adrenoceptor agonists in the treatment of overactive bladder syndrome - insight from transcriptosome and experimental studies.

Michel MC, Gravas S.

Expert Opin Drug Saf. 2016 May;15(5):647-57. doi: 10.1517/14740338.2016.1160055. Epub 2016 Mar 21. Review.

PMID:
26954275
16.

[MIRABEGRON--A NEW DRUG FOR TREATMENT OF OVERACTIVE BLADDER].

Kasjan GR.

Urologiia. 2015 Jul-Aug;(4):121-4. Review. Russian.

PMID:
26665779
17.

[Pharmacological and clinical profile of mirabegron (Betanis(®)): a new therapeutic agent for overactive bladder].

Suzuki M, Ukai M, Sasamata M, Seki N.

Nihon Yakurigaku Zasshi. 2012 May;139(5):219-25. Review. Japanese. No abstract available.

PMID:
22687876
18.

Profile of mirabegron in the treatment of overactive bladder: place in therapy.

Sharaf A, Hashim H.

Drug Des Devel Ther. 2017 Feb 20;11:463-467. doi: 10.2147/DDDT.S101630. eCollection 2017. Review.

Supplemental Content

Support Center